Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1974 1
1976 1
1981 4
1982 1
1983 3
1984 2
1985 5
1986 1
1987 6
1988 3
1989 1
1990 2
1991 6
1992 2
1993 8
1994 6
1995 8
1996 13
1997 12
1998 21
1999 17
2000 14
2001 24
2002 18
2003 29
2004 21
2005 35
2006 32
2007 27
2008 35
2009 31
2010 43
2011 29
2012 38
2013 46
2014 43
2015 45
2016 66
2017 53
2018 53
2019 42
2020 56
2021 51
2022 69
2023 60
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

993 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: evers s. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677. Online ahead of print. Clin Cancer Res. 2024. PMID: 38709220
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodriguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I. Steeghs N, et al. Among authors: evers s. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-3567. Online ahead of print. Clin Cancer Res. 2024. PMID: 38630781
The laboratory parameters-derived CoLab score as an indicator of the host response in ICU COVID-19 patients decreases over time: a prospective cohort study.
Schoenmakers T, Leers MPG, Gorissen SHM, van Loo IHM, van Rosmalen F, Aydeniz E, Schellens J, Driessen M, Deneer R, de Venne WPHGV, Wolffs PFG, van Mook WNKA, van Bussel BCT; CoLaIC-consortium. Schoenmakers T, et al. Sci Rep. 2024 Apr 8;14(1):8220. doi: 10.1038/s41598-024-58727-y. Sci Rep. 2024. PMID: 38589581 Free PMC article.
993 results